Skip to content
RKWD
ROCKWOOD RESEARCH · A CORPORATE FILINGS WEBSITE|STRAIGHT FROM THE SOURCE · SEC EDGAR|SPONSOREDYour message on this tape — bid on the Rockwood Ad Exchange · Rockwood Ad Exchange|
Rockwood Research
…

NTLA

Intellia Therapeutics, Inc.

In Vitro & In Vivo Diagnostic Substances · SIC 2835CIK 1652130Held by 4 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:XLINKEDINEMAIL
Revenue FY2025
$68.0M
Net Income FY2025
$(413.0M)
EPS (Basic, as reported)
$-3.81
Net Margin FY2025
-609.9%
ROE FY2025
-61.5%
Total Equity
$671.0M
Shares Out
140M
Business description

Intellia Therapeutics, Inc. — In Vitro & In Vivo Diagnostic Substances. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2015–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions
i
default rows · click any row to chart itRevenue: 16 → 68 +17.4% CAGR
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue16263043583352365868
Cost of revenue——0000————
Research & development(32)(68)(89)(108)(150)(230)(420)(435)(466)(389)
General & administrative(17)(28)(32)(41)(44)(71)(90)(116)(126)(120)
Total operating expenses(49)(96)(121)(149)(195)(301)(510)(552)(592)(509)
Operating income(32)(70)(91)(106)(137)(268)(458)(515)(534)(441)
Interest & investment income1267219504829
Other income (expense), net———720(16)341528
Pre-tax income(32)(68)————————
Income tax expense0————————0
Net income(32)(68)(85)(100)(134)(268)(474)(481)(519)(413)
EPS — basic————($2.40)($3.78)($6.16)($5.42)($5.25)($3.81)
EPS — diluted————($2.40)($3.78)($6.16)($5.42)($5.25)($3.81)
Shares outstanding — basic (M)————5671778999108
Shares outstanding — diluted (M)————5671778999108

Showing the latest 10 of 11 fiscal years.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.